9-(4-methoxyphenyl)xanthene | 19234-05-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 9-(4-methoxyphenyl)xanthene
• 英文别名: 9-(4-methoxyphenyl)-9H-xanthene
• CAS: 19234-05-0
• 化学式: C₂₀H₁₆O₂
• 分子量: 288.346
• InChiKey: HOPFKLWRUOJYHS-UHFFFAOYSA-N

物化性质

• 熔点：
  113-114 °C(Solv: ethanol (64-17-5))
• 沸点：
  395.8±31.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  9-(4-methoxyphenyl)xanthene 在 air 、 苯 作用下， 生成 bis-[9-(4-methoxy-phenyl)-xanthen-9-yl]-peroxide
  参考文献：
  名称：

  Schoenberg; Mustafa, Journal of the Chemical Society, 1947, p. 997,1000

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 锌 作用下， 生成 9-(4-methoxyphenyl)xanthene
  参考文献：
  名称：

  Gomberg; Snow, Journal of the American Chemical Society, 1925, vol. 47, p. 209

  摘要：

  DOI：

文献信息

• PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES
  申请人：AM CHEMICALS LLC

  公开号：US20160083414A1

  公开（公告）日：2016-03-24

  Novel nucleoside phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one phosphotriester linkage conjugated to a monosaccharide and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said building blocks, preferably followed by removal of protecting groups to provide monosaccharide-conjugated oligonucleotides.

  揭示了用于制备含至少一种磷酸三酯键连接的寡核苷酸的合成寡核苷酸的新型核苷酸磷酰胺酯构建模块，其与单糖偶联，并公开了制备这些构建模块的合成过程。此外，使用这些构建模块制备寡聚合物化合物，最好是在去除保护基之后，以提供单糖偶联的寡核苷酸。
• SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE CONJUGATES
  申请人：AM Chemicals LLC

  公开号：US20180016232A1

  公开（公告）日：2018-01-18

  Novel non-nucleoside solid supports and phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one non-nucleosidic moiety conjugated to a ligand of practical interest and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said solid supports and phosphoramidite building blocks, preferably followed by removal of protecting groups to provide oligonucleotides conjugated to ligands of interest.

  揭示了用于制备含有至少一个非核苷酸基团与实用兴趣配体共轭的合成寡核苷酸的新型非核苷酸固相支持体和磷酰胺酸酯构建块，以及制备这些固相支持体和磷酰胺酸酯构建块的合成过程。此外，使用所述固相支持体和磷酰胺酸酯构建块制备寡聚合物化合物，最好是在去除保护基的情况下，以提供与感兴趣的配体共轭的寡核苷酸。
• Universal building blocks and support media for synthesis of oligonucleotides and their analogs
  申请人：——

  公开号：US20040152905A1

  公开（公告）日：2004-08-05

  Compounds for the synthesis of oligomeric compounds, particularly oligonucleotides and chemically modified oligonucleotide analogs, are provided. In addition, methods for functionalization of a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.

  提供用于合成寡聚化合物，特别是寡核苷酸和化学修饰的寡核苷酸类似物的化合物。此外，还提供了将支持介质功能化为第一单体亚基的方法，以及利用与支持介质结合的新化合物合成寡聚化合物的方法。
• SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
  申请人：Alios BioPharma, Inc.

  公开号：US20150105341A1

  公开（公告）日：2015-04-16

  Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.

  本文披露了核苷、核苷酸和核苷酸类似物，以及它们的合成方法以及利用一个或多个核苷、核苷酸和核苷酸类似物治疗如小核糖核病毒和/或黄病毒科感染等疾病和/或症状的方法。
• Labeled oligonucleotides, methods for making same, and compounds useful therefor
  申请人：——

  公开号：US20030208061A1

  公开（公告）日：2003-11-06

  Selectively functionalized oligonucleotides, methods for making same, and compounds useful therefor are disclosed. The oligonucleotides can be selectively functionalized with a first conjugate group at the 3′-terminial position and optionally functionalized with a second conjugate group at the 5′-terminal position and/or one or more internucleotides. Alternatively, the oligonucleotides can be selectively functionalized with a first conjugate group at the 5′-terminal position and optionally functionalized with a second conjugate group at one or more internucleotides. In yet another embodiment, the oligonucleotides can be functionalized with a first conjugate group at one or more internucleotides and with a second conjugate group at one or more different internucleotides.

  选择性功能化寡核苷酸，制备方法以及用于此目的的化合物已被披露。这些寡核苷酸可以在3'-末端位置选择性地与第一共轭基团功能化，并可选择性地在5'-末端位置和/或一个或多个核苷酸之间与第二共轭基团功能化。另外，这些寡核苷酸可以在5'-末端位置选择性地与第一共轭基团功能化，并可选择性地在一个或多个核苷酸之间与第二共轭基团功能化。在另一实施方式中，这些寡核苷酸可以在一个或多个核苷酸之间与第一共轭基团功能化，并在一个或多个不同的核苷酸之间与第二共轭基团功能化。